Nephrology

Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy

Retrieved on: 
Thursday, January 25, 2024

BRISBANE, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced positive 72-week data from the open label extension (OLE) period of its Phase 2b ORIGIN clinical trial of atacicept in participants with IgA nephropathy (IgAN). In aggregate, the 72-week data with atacicept are consistent with a profile of true disease modification in IgAN.

Key Points: 
  • In aggregate, the 72-week data with atacicept are consistent with a profile of true disease modification in IgAN.
  • “Data from the OLE show the consistent and sustained reductions of Gd-lgA1, hematuria, and UPCR, as well as the stability of eGFR over 72 weeks in participants with IgAN.
  • “We are thrilled to present this package of positive new data from the OLE of the Phase 2b ORIGIN clinical trial during our R&D Day, which will be held today in New York.
  • The R&D Day presentation, which includes the OLE 72-Week data slides and commentary, will be available on the Company’s website at the Investor Calendar .

Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones

Retrieved on: 
Tuesday, January 23, 2024

LOS ALTOS, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today issued a letter to shareholders.

Key Points: 
  • As I sit down to write this letter, I am filled with a profound sense of gratitude and excitement, energized for the year ahead.
  • In this letter, I am pleased to recap for you another year of great accomplishments.
  • We’ve made significant advancements in our clinical programs which will propel us to new heights in 2024.
  • I would like to express my deep appreciation to the physician investigators, study participants, and especially to our dedicated Unicycive employees.

Kane Biotech Announces Special Meeting of Shareholders

Retrieved on: 
Thursday, January 18, 2024

WINNIPEG, Manitoba, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces today that on February 20, 2024, the Company will hold a special meeting of its shareholders (the “Meeting”) to consider the election of Dr. Robert Huizinga as an additional director of the Company.

Key Points: 
  • WINNIPEG, Manitoba, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces today that on February 20, 2024, the Company will hold a special meeting of its shareholders (the “Meeting”) to consider the election of Dr. Robert Huizinga as an additional director of the Company.
  • The information circular and other materials with respect to the Meeting will be filed on SEDAR+ by the Company in due course.
  • Dr. Huizinga holds a PhD in Organizational Leadership, a Masters in Clinical Epidemiology, holds his Nephrology certification and is a member of Sigma Theta Tau.
  • Dr. Huizinga has been a member of Kane Biotech’s Scientific Advisory Board since 2018.

CORE Kidney's “Gift of Life: A Tune That Never Fades” Float Wins the Hearts of Rose Parade® Crowd, Recognized With 2024 Isabella Coleman Award

Retrieved on: 
Tuesday, January 16, 2024

A special thanks to Lyn Lofthouse for the floral decorations that won us the Isabella Coleman Award.

Key Points: 
  • A special thanks to Lyn Lofthouse for the floral decorations that won us the Isabella Coleman Award.
  • We are also very grateful to Steve Perry and the Tournament of Roses team for supporting us all along.
  • The float with the kidney-shaped tree sat living kidney donors, kidney health champions, in a beautiful colorful garden as they danced to, “Dancing in the Streets” tune!
  • CORE Kidney’s Rose Parade float was sponsored by Amgen, Baxter International, DaVita and Travere Therapeutics, who made it possible to feature living kidney donors on the float.

Bond Biosciences Announces Successful Pre-IND Meeting with the FDA to Advance the Development of BBI-001 for Treatment of Iron Overload Associated with Hereditary Hemochromatosis

Retrieved on: 
Thursday, January 11, 2024

BBI-001 is a novel investigational new drug.

Key Points: 
  • BBI-001 is a novel investigational new drug.
  • It is a non-absorbed, oral therapeutic designed to rapidly form a strong and selective iron chelate in the digestive tract, thus inhibiting iron absorption in patients with symptomatic iron overload due to HH.
  • The structure and properties of BBI-001 have been designed to restrict it to the GI tract to inhibit systemic expose.
  • “FDA was very thoughtful in reviewing the Bond briefing package and replying in depth on the proposed non-clinical and clinical development program options, to facilitate the next Phase of clinical development” observed Curtis L. Scribner, MD, Bond’s Chief Medical Officer.

Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities

Retrieved on: 
Monday, January 8, 2024

WALTHAM, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today provided an update on the company’s progress in 2023 and initial expectations for 2024.

Key Points: 
  • “2023 was a landmark year for Ardelyx, marking our first full year as a commercial entity and the approval and launch of our second first-in-class product.
  • XPHOZAH® joins IBSRELA in our portfolio of important treatment options for patients with unmet needs,” said Mike Raab, president and chief executive officer.
  • We are poised to continue with a growth trend in 2024.
  • Ardelyx currently expects full-year 2024 U.S. net product sales revenue for IBSRELA to be between $140.0 and $150.0 million.

Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer

Retrieved on: 
Monday, January 8, 2024

The company has appointed Robert M. Brenner, M.D., as Chief Medical Officer to succeed Dr. Celia Lin, M.D.

Key Points: 
  • The company has appointed Robert M. Brenner, M.D., as Chief Medical Officer to succeed Dr. Celia Lin, M.D.
  • ; and William D. Turner as Chief Development Officer, effective immediately.
  • Rob and Bill each have successfully guided multiple therapies through late clinical development, regulatory approval and commercial launch.
  • This is a key moment for Vera as we continue to advance the strategy for our late-stage clinical program,” said Marshall Fordyce, M.D., Chief Executive Officer of Vera Therapeutics.

Use of SGLT2 Inhibitors Continues to Expand for the Treatment of Chronic Kidney Disease, with Eli Lilly/Boehringer Ingelheim’s Jardiance Making Significant Strides Following Label Expansion

Retrieved on: 
Wednesday, January 3, 2024

As the landscape grows more competitive, their role will be crucial in determining the success of brands like Farxiga and Jardiance.

Key Points: 
  • As the landscape grows more competitive, their role will be crucial in determining the success of brands like Farxiga and Jardiance.
  • This unique positioning compared to other agents was swiftly recognized by nephrologists, prompting them to express a clear preference for the brand.
  • Since the label expansion of Eli Lilly/Boehringer Ingelheim's Jardiance to include CKD, nephrologists have rapidly embraced this drug for both their DKD and non-diabetic CKD patients.
  • Several of these agents, including SGLT2 inhibitors and Kerendia, have demonstrated their effectiveness in slowing the progression of CKD.

XORTX Welcomes New Member to the Board of Directors

Retrieved on: 
Tuesday, January 2, 2024

CALGARY, Alberta, Jan. 02, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes Mr. Patrick Treanor to the Board of Directors and announces the resignation of Ian Klassen, both effective December 31, 2023.

Key Points: 
  • CALGARY, Alberta, Jan. 02, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes Mr. Patrick Treanor to the Board of Directors and announces the resignation of Ian Klassen, both effective December 31, 2023.
  • He previously served as President, US for Vifor Pharma, an international pharmaceutical company focused on nephrology.
  • Mr. Treanor currently serves on the board of directors of KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors.
  • Anthony Giovinazzo, Chair of XORTX, stated, “We are very pleased to have Patrick Treanor agree to join the XORTX board.

In Vitro Diagnostics Analyzers Market Analysis Reveals Impressive Growth Forecast Through 2028 with Focus on Key Drivers and Trends - ResearchAndMarkets.com

Retrieved on: 
Friday, December 29, 2023

The increasing elderly population, growing incidence of chronic diseases, widening use of diagnostics for prevention and monitoring, and growing adoption of PoC testing are driving market growth.

Key Points: 
  • The increasing elderly population, growing incidence of chronic diseases, widening use of diagnostics for prevention and monitoring, and growing adoption of PoC testing are driving market growth.
  • Based on analyzer type, the market is categorized into immunoassay analyzers, clinical chemistry analyzers, hematology and hemostasis analyzers, molecular diagnostic analyzers and PoC analyzers.
  • The molecular analyzers segment, which held the third largest market share in 2022, is expected to show the highest CAGR, at 6.0%, during the forecast period.
  • The current report highlights the current and future market potential of in vitro diagnostics analyzers along with an analysis of the drivers, restraints, challenges, and emerging trends in the market.